Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:58 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 524412 | NSE: AAREYDRUGS

Aarey Drugs & Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹55.79Fairly Valued by 4.67%vs CMP ₹53.30

P/E (44.0) × ROE (3.0%) × BV (₹52.50) × DY (2.00%)

₹46.52Overvalued by 12.72%vs CMP ₹53.30
MoS: -14.6% (Negative)Confidence: 38/100 (Low)Models: 2 Under, 1 Fair, 3 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹47.9534%Over (-10%)
Graham NumberEarnings₹37.8125%Over (-29.1%)
Net Asset ValueAssets₹52.2411%Fair (-2%)
Earnings YieldEarnings₹12.1011%Over (-77.3%)
ROCE CapitalReturns₹62.5211%Under (+17.3%)
Revenue MultipleRevenue₹83.668%Under (+57%)
Consensus (6 models)₹46.52100%Overvalued
Key Drivers: ROE 3.0% is below cost of equity. | Wide model spread (₹12–₹84) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -14.1%

*Investments are subject to market risks

Investment Snapshot

43
Aarey Drugs & Pharmaceuticals Ltd scores 43/100 (Weak)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health62/100 · Moderate
ROCE 6.4% WeakROE 3.0% WeakD/E 0.18 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money55/100 · Moderate
FII holding up 1.52% (6mo) AccumulatingPromoter decreased by 5.75% Caution
Earnings Quality50/100 · Moderate
OPM stable around 1% Steady
Quarterly Momentum15/100 · Weak
Revenue (4Q): -32% YoY DecliningProfit (4Q): -40% YoY DecliningOPM: -1.6% (down 3.2% YoY) Margin pressure
Industry Rank20/100 · Weak
P/E 44.0 vs industry 53.8 In-lineROCE 6.4% vs industry 16.4% Below peersROE 3.0% vs industry 15.2% Below peers3Y sales CAGR: -1% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:58 am

Market Cap 151 Cr.
Current Price 53.3
Intrinsic Value₹46.52
High / Low 100/41.1
Stock P/E44.0
Book Value 52.5
Dividend Yield0.00 %
ROCE6.38 %
ROE2.96 %
Face Value 10.0
PEG Ratio-3.13

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Aarey Drugs & Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Aarey Drugs & Pharmaceuticals Ltd 151 Cr. 53.3 100/41.144.0 52.50.00 %6.38 %2.96 % 10.0
Coral Laboratories Ltd 137 Cr. 383 785/3609.57 5960.39 %17.4 %13.1 % 10.0
Auro Laboratories Ltd 169 Cr. 272 317/15957.4 69.90.00 %3.85 %4.33 % 10.0
Achyut Healthcare Ltd 132 Cr. 5.62 6.80/3.00308 1.340.00 %2.26 %1.77 % 1.00
Brooks Laboratories Ltd 131 Cr. 44.5 166/36.36.07 39.30.00 %9.93 %12.2 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Aarey Drugs & Pharmaceuticals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 62.47162.8850.9657.8376.48210.35126.91105.14133.79108.10102.2184.1696.43
Expenses 60.94160.3649.6255.9973.78211.79125.73101.42131.59112.31100.5081.5297.94
Operating Profit 1.532.521.341.842.70-1.441.183.722.20-4.211.712.64-1.51
OPM % 2.45%1.55%2.63%3.18%3.53%-0.68%0.93%3.54%1.64%-3.89%1.67%3.14%-1.57%
Other Income 0.480.840.700.840.295.141.580.020.687.541.550.794.18
Interest 0.710.200.420.410.470.400.960.490.581.301.041.260.92
Depreciation 0.551.020.891.271.061.150.471.510.900.410.490.690.83
Profit before tax 0.752.140.731.001.462.151.331.741.401.621.731.480.92
Tax % -33.33%83.18%0.00%-22.00%30.14%-0.47%6.77%8.62%48.57%71.60%20.81%31.08%38.04%
Net Profit 1.000.360.721.231.022.151.241.600.720.471.371.020.57
EPS in Rs 0.390.140.280.480.400.770.440.570.250.170.480.360.20

Last Updated: March 3, 2026, 1:18 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 1:41 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 200213246396349354298348493419396474391
Expenses 198212245386342347294344481411391471392
Operating Profit 11110883511843-1
OPM % 1%1%0%2%2%2%1%1%2%2%1%1%-0%
Other Income 233334773371014
Interest 1124222223455
Depreciation 1111111122222
Profit before tax 11288978106566
Tax % 22%23%29%31%25%27%20%21%35%37%12%34%
Net Profit 1115676774543
EPS in Rs 0.620.650.773.022.642.802.482.782.581.491.671.421.21
Dividend Payout % 0%0%0%0%0%4%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%0.00%400.00%20.00%16.67%-14.29%16.67%0.00%-42.86%25.00%-20.00%
Change in YoY Net Profit Growth (%)0.00%0.00%400.00%-380.00%-3.33%-30.95%30.95%-16.67%-42.86%67.86%-45.00%

Aarey Drugs & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:8%
5 Years:10%
3 Years:-1%
TTM:-5%
Compounded Profit Growth
10 Years:14%
5 Years:-7%
3 Years:-15%
TTM:-26%
Stock Price CAGR
10 Years:18%
5 Years:16%
3 Years:20%
1 Year:-3%
Return on Equity
10 Years:6%
5 Years:4%
3 Years:3%
Last Year:3%

Last Updated: September 5, 2025, 2:01 pm

Balance Sheet

Last Updated: December 4, 2025, 2:15 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 17171718232323232525282828
Reserves 18192031576369758892105110120
Borrowings 611151031618181438313551
Other Liabilities 6769748386438411611713613911794
Total Liabilities 107115125142170146194233245291303291294
Fixed Assets 46812121212141414131625
CWIP 0000000000000
Investments 0000000000122
Other Assets 102109117130157133181218230277289272267
Total Assets 107115125142170146194233245291303291294

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -0361-201350-1-310
Cash from Investing Activity + 2-2-3-5-1-1-1-3-30-2-6
Cash from Financing Activity + -1-2-2423-2-2-2216-4
Net Cash Flow 0-11-12-300-011-0
Free Cash Flow -113-4-21-123-2-2-45
CFO/OP -32%239%560%28%-232%37%135%154%36%13%-37%421%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-5.00-10.00-14.000.005.00-8.00-15.00-13.00-3.00-30.00-27.00-32.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 11911410875100109118170101165170103
Inventory Days 107351623212011263336
Days Payable 119117108718440981208611512381
Cash Conversion Cycle 95393292426926768058
Working Capital Days 5249403469779991688910689
ROCE %6%7%7%22%14%12%8%9%10%6%6%6%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 50.05%50.04%50.04%50.04%45.28%45.28%45.44%44.80%44.80%44.80%44.80%39.05%
FIIs 3.92%3.92%3.94%3.83%3.40%3.40%2.75%2.34%2.34%1.97%1.13%3.86%
Public 46.04%46.03%46.01%46.12%51.31%51.32%51.81%52.86%52.86%53.23%54.07%57.09%
No. of Shareholders 17,69917,53816,08615,26916,84316,17916,67616,28816,25715,79614,89714,063

Shareholding Pattern Chart

No. of Shareholders

Aarey Drugs & Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 1.421.671.492.722.79
Diluted EPS (Rs.) 1.421.671.492.722.79
Cash EPS (Rs.) 2.102.272.113.363.18
Book Value[Excl.RevalReserv]/Share (Rs.) 48.6747.3346.2544.7742.27
Book Value[Incl.RevalReserv]/Share (Rs.) 48.6747.3346.2544.7742.27
Revenue From Operations / Share (Rs.) 166.56141.02165.04194.09148.99
PBDIT / Share (Rs.) 4.474.074.125.524.98
PBIT / Share (Rs.) 3.783.463.504.744.59
PBT / Share (Rs.) 2.141.902.373.953.55
Net Profit / Share (Rs.) 1.411.671.492.582.79
PBDIT Margin (%) 2.682.882.492.843.34
PBIT Margin (%) 2.272.452.112.443.08
PBT Margin (%) 1.281.351.432.032.38
Net Profit Margin (%) 0.841.180.901.321.86
Return on Networth / Equity (%) 2.903.523.215.756.58
Return on Capital Employeed (%) 7.617.107.2010.4410.68
Return On Assets (%) 1.381.541.292.662.79
Long Term Debt / Equity (X) 0.010.020.030.000.00
Total Debt / Equity (X) 0.250.230.320.120.18
Asset Turnover Ratio (%) 1.601.331.562.061.63
Current Ratio (X) 1.781.701.611.741.65
Quick Ratio (X) 1.481.491.441.631.51
Inventory Turnover Ratio (X) 11.830.000.000.000.00
Interest Coverage Ratio (X) 2.732.613.657.014.79
Interest Coverage Ratio (Post Tax) (X) 1.862.072.324.273.68
Enterprise Value (Cr.) 129.30155.1097.10119.0671.62
EV / Net Operating Revenue (X) 0.270.390.230.240.20
EV / EBITDA (X) 10.1713.599.298.506.15
MarketCap / Net Operating Revenue (X) 0.200.310.140.210.15
Price / BV (X) 0.690.940.510.920.54
Price / Net Operating Revenue (X) 0.200.310.140.210.15
EarningsYield 0.040.030.060.060.12

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Aarey Drugs & Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 15/05/1990 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1990PLC056538 and registration number is 056538. Currently Company is involved in the business activities of Activities of commission agents dealing in wholesale trade inwood, paper, skin, leather and fur, fuel, petroleum products, chemicals, perfumery and cosmetics, glass, minerals, ores and metals. Company's Total Operating Revenue is Rs. 473.94 Cr. and Equity Capital is Rs. 28.45 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsE-34, M.I.D.C., Thane Maharashtra 401506Contact not found
Management
NamePosition Held
Mr. Mihir R GhataliaChairman & Managing Director
Mr. Nimit Rajesh GhataliaExecutive Director
Ms. Bina Rajesh GhataliaWoman Director
Mr. Chetan K MehtaIndependent Director
Mr. Anil MandalIndependent Director
Mr. Lalit Radhakrishna TulsianiIndependent Director

FAQ

What is the intrinsic value of Aarey Drugs & Pharmaceuticals Ltd and is it undervalued?

As of 14 April 2026, Aarey Drugs & Pharmaceuticals Ltd's intrinsic value is ₹46.52, which is 12.72% lower than the current market price of ₹53.30, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (2.96 %), book value (₹52.5), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Aarey Drugs & Pharmaceuticals Ltd?

Aarey Drugs & Pharmaceuticals Ltd is trading at ₹53.30 as of 14 April 2026, with a FY2026-2027 high of ₹100 and low of ₹41.1. The stock is currently near its 52-week low. Market cap stands at ₹151 Cr..

How does Aarey Drugs & Pharmaceuticals Ltd's P/E ratio compare to its industry?

Aarey Drugs & Pharmaceuticals Ltd has a P/E ratio of 44.0, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Aarey Drugs & Pharmaceuticals Ltd financially healthy?

Key indicators for Aarey Drugs & Pharmaceuticals Ltd: ROCE of 6.38 % is on the lower side compared to the industry average of 16.35%; ROE of 2.96 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Aarey Drugs & Pharmaceuticals Ltd profitable and how is the profit trend?

Aarey Drugs & Pharmaceuticals Ltd reported a net profit of ₹4 Cr in Mar 2025 on revenue of ₹474 Cr. Compared to ₹7 Cr in Mar 2022, the net profit shows a declining trend.

Does Aarey Drugs & Pharmaceuticals Ltd pay dividends?

Aarey Drugs & Pharmaceuticals Ltd has a dividend yield of 0.00 % at the current price of ₹53.30. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Aarey Drugs & Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports